Abstract

Adult T-cell leukemia (ATL) is an aggressive T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1) infection and often occurs in HTLV-1-endemic areas, such as southwestern Japan, the Caribbean islands, Central and South America, Intertropical Africa, and Middle East. To date, many epidemiological studies have been conducted to investigate the incidence of ATL among general population or HTLV-1 carriers and to identify a variety of laboratory, molecular, and host-specific markers to be possible predictive factors for developing ATL because HTLV-1 infection alone is not sufficient to develop ATL. This literature review focuses on the epidemiology of ATL and the risk factors for the development of ATL from HTLV-1 carriers, while keeping information on the epidemiology of HTLV-1 to a minimum. The main lines of epidemiological evidence are: (1) ATL occurs mostly in adults, at least 20–30 years after the HTLV-1 infection, (2) age at onset differs across geographic areas: the average age in the Central and South America (around 40 years old) is younger than that in Japan (around 60 years old), (3) ATL occurs in those infected in childhood, but seldom occurs in those infected in adulthood, (4) male carriers have about a three- to fivefold higher risk of developing ATL than female, (5) the estimated lifetime risk of developing ATL in HTLV-1 carriers is 6–7% for men and 2–3% for women in Japan, (6) a low anti-Tax reactivity, a high soluble interleukin-2 receptor level, a high anti-HTLV-1 titer, and high levels of circulating abnormal lymphocytes and white blood cell count are accepted risk factors for the development of ATL, and (7) a higher proviral load (more than 4 copies/100 peripheral blood mononuclear cells) is an independent risk factor for progression of ATL. Nevertheless, the current epidemiological evidence is insufficient to fully understand the oncogenesis of ATL. Further well-designed epidemiological studies are needed.

Highlights

  • Adult T-cell leukemia (ATL) was first reported as a distinct clinical entity in Japan in 1977 (Takatsuki et al, 1977; Uchiyama et al, 1977)

  • Two studies reported that expression of CD3, CD7, and CD26 on HTLV-1-infected cells were diminished in acute and chronic ATL and those were slightly down-regulated in smoldering ATL (Tsuji et al, 2004; Tian et al, 2011). These results suggest that the down-regulation of those cell-surface antigens could be possible predict markers for the early phase leukemogenesis of ATL from HTLV-1 carriers

  • CONCLUDING REMARKS many prior studies found important epidemiological evidence on ATL and risk factors for the development of ATL in HTLV-1 carriers, limited data are available on the valid annual incidence of ATL from longitudinal prospective studies

Read more

Summary

INTRODUCTION

Adult T-cell leukemia (ATL) was first reported as a distinct clinical entity in Japan in 1977 (Takatsuki et al, 1977; Uchiyama et al, 1977). ATL patients have been reported mainly from HTLV-1-endemic areas. The main endemic areas are Japan, the Caribbean islands, Central and South America, Central and South Africa, a part of the Middle East and Melanesia, and Aboriginal regions in Australia (IARC, 1996). Regional clustering of virus positivity and high incidence of ATL has been detected even within the endemic areas. A variety of study designs and settings, e.g., case series, nation wide surveys, and regional population-based studies using cancer registries were reported to assess incidence, prevalence, and other epidemiological www.frontiersin.org. Readers should keep in mind that all epidemiological studies have individual limitations in the case accumulation and the population setting

INCIDENCE AND PREVALENCE
No ATL cases
Whole Japanese population Data from the Statistics
Whole French Guiana population
White population in US Black population in US
Findings
Year of survey

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.